Dapi Website: Über die Autoren

Kieble, Marita

Referentin für Pharmakoepidemiologie, Deutsches Arzneiprüfungsinstitut e. V. (DAPI), Berlin

Publikationen:

Impact On Antihypertensive Prescribing After The Dear Healthcare Professional Letter On Increased Risk Of Skin Cancer Related To Hydrochlorothiazide

Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave

Quality Appraisal of Ambulatory Oral Cephalosporin and Fluoroquinolone Use in the 16 German Federal States from 2014–2019

Changes in utilization of antihypertensive drugs following angiotensin receptor blocker product recalls in Germany

Innovative Hepatitis-C-Arzneimittel - Was der Zusatznutzen wirklich kostet

Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study

DAPI-Zahlen aus Rheinland-Pfalz. Die 10 häufigsten Wirkstoffe mit pharmazeutischen Bedenken

DAPI-Zahlen aus Berlin. Die 10 häufigsten Wirkstoffe mit pharmazeutischen Bedenken

Temporal synchrony between drug dispensings and adverse drug events? The example of statins & rhabdomyolysis and metamizole or clozapine & agranulocytosis

Oral Antibiotics in Germany and the Netherlands in Primary Care from 2012 – 2016: A Comparison

In search of a standard when analyzing medication adherence in patients with heart failure using claims data: a systematic review.

Comparing outpatient oral antibiotic use in Germany and the Netherlands from 2012 to 2016

Fixkombinationen von Antihypertensiva auf dem deutschen Markt - Fixkombinationen von ACE-Hemmern, Angiotensin-II-Rezeptorblockern, Betablockern, Calciumkanalblockern und Diuretika

Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany

“Dear Doctor” Warning Letter (Rote-Hand-Brief) on Hydrochlorothiazide and Its Impact on Antihypertensive Prescription